Sylvester establishes Diversity in Cancer Research Internship Program

Researchers have identified groups of patients with pleural mesothelioma, a rare and aggressive cancer, who are more likely to respond to immunotherapy, offering clues about why only some tumors respond to the treatment.

Many therapeutic molecules used in cancer treatments are highly toxic, often harming healthy tissues and causing significant side effects. This creates a critical need for strategies that localize their toxic activity to tumors. What if cancer drugs could stay dormant until they reach cancer cells? A study by Syracuse University researchers demonstrates a promising chemistry-based strategy that could do just that.